Close

TS-Fluc Anti-GD2 (XW-444) 28BBζ CAR (XS-0822-YF9201)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-Human GD2 chimeric antigen receptor (CAR) is constructed for the engineering of T cells. The receptor construction is 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ. 7H-YB means seven repeats of the HSE motif 5'-nGAAnnTTCnnGAAn-3' upstream of the human synthetic core promoter (YB). 7H-YB is a technology for photothermal control of T cell therapies.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • GD2
  • Targeting Diseases
  • Brain Cancer; Melanoma; Neuroblastoma; Osteosarcoma
  • Generation
  • Third-generation CAR
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • 7H-YB-Fluc-EF1a-scFv-CD28-41BB-CD3ζ

Target

  • Clone
  • XW-444
  • Host
  • Humanized
  • Target Species
  • Human
  • Gene Name
  • Ganglioside GD2
  • Synonyms
  • GD2 ganglioside; GD2
  • Introduction
  • Gangliosides are carbohydrate-containing sphingolipids that are widely expressed in normal tissues, making most subtypes unsuitable as targets for cancer therapy. However, the disialoganglioside GD2 subtype has limited expression in normal tissues but is overexpressed across a wide range of tumors. Disialoganglioside GD2 can be considered a tumor-associated antigen and well-suited as a target for cancer therapy. Disialoganglioside GD2 is implicated in tumor development and malignant phenotypes through enhanced cell proliferation, motility, migration, adhesion, and invasion, depending on the tumor type. This provides a rationale for targeting disialoganglioside GD2 in cancer therapy with the development of anti-GD2 monoclonal antibodies and other therapeutic approaches.

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System

Customer Reviews and Q&As

There are currently no customer reviews or questions for TS-Fluc Anti-Human GD2 scFv (XW-444) CD28-41BB-CD3ζ CAR, pCDCAR1 (XS-0822-YF9201). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.